ReviewEpigenomics2015
High-throughput screening to identify inhibitors of lysine demethylases.
Review in Epigenomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Comparative analysis for optimal LSD1 inhibitors evaluation techniques: pros and cons.Journal of pharmaceutical analysis · 2026Review
- Gene Regulation and Mitochondrial Activity During White and Brown Adipogenesis Are Modulated by KDM5 Histone Demethylase.Journal of the Endocrine Society · 2024Article
- Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells.Investigational new drugs · 2023Article
- Lysine Demethylation in Pathogenesis.Advances in experimental medicine and biology · 2023Article
- Exiting the tunnel of uncertainty: crystal soak to validated hit.Acta crystallographica. Section D, Structural biology · 2022Article
- Machine-Learning-Enabled Virtual Screening for Inhibitors of Lysine-Specific Histone Demethylase 1.Molecules (Basel, Switzerland) · 2021Article
- Histone methylation and acetylation in macrophages as a mechanism for regulation of inflammatory responses.Journal of cellular physiology · 2018Review
- The Emerging Role of Histone Demethylases in Renal Cell Carcinoma.Journal of kidney cancer and VHL · 2017Review
- Epigenetic assays for chemical biology and drug discovery.Clinical epigenetics · 2017Review
- Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.Oncotarget · 2016Article
- LSD1 Histone Demethylase Assays and Inhibition.Methods in enzymology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lysine demethylases (KDMs) are epigenetic regulators whose dysfunction is implicated in the pathology of many human diseases including various types of cancer, inflammation and X-linked intellectual disability. Particular demethylases have been identified as promising therapeutic targets, and tremendous efforts are being devoted toward developing suitable small-molecule inhibitors for clinical and research use. Several High-throughput screening strategies have been developed to screen for small-molecule inhibitors of KDMs, each with advantages and disadvantages in terms of time, cost, effort, reliability and sensitivity. In this Special Report, we review and evaluate the High-throughput screening methods utilized for discovery of novel small-molecule KDM inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.